Advertisement

In-Hospital Outcomes and Predictors of Mortality for Redo Surgical Mitral Valve Replacement Versus Transcatheter Mitral Valve-in-Valve Replacement

      Durability is a major limitation with bioprosthetic heart valves. For mitral valve prosthesis dysfunction, redo surgical mitral valve replacement (rSMVR) has been the mainstay of treatment; however, transcatheter mitral valve-in-valve replacement (mViV) has emerged as a viable alternative. Data comparing these procedures remains limited; therefore, we sought to compare the real-world in-hospital mortality, likelihood of adverse peri-operative outcomes, and predictors of mortality between rSMVR versus mViV using the National Inpatient Sample. During the study period, a weighted total of 1,890 patients (78%) underwent rSMVR, and 520 (22%) underwent mViV. After propensity matching, there were 310 patients in each cohort. There was no statistically significant difference in mortality with these procedures (odds ratio 1.53; 95% confidence interval 0.67 to 3.45; p = 0.31). rSMVR was associated with increased length of hospitalization (13 vs 7.5 days; p <0.001), increased medical costs ($324,124 vs $241,147; p <0.001), and increased peri-operative complications compared with mViV. Predictors of mortality unique to rSMVR were age >75 years, cirrhosis, sleep apnea, malnourishment/low body mass index, and obesity, signalizing greater suitability for mViV in these populations.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Rodriguez-Gabella T
        • Voisine P
        • Puri R
        • Pibarot P
        • Rodés-Cabau J.
        Aortic bioprosthetic valve durability: incidence, mechanisms, predictors, and management of surgical and transcatheter valve degeneration.
        J Am Coll Cardiol. 2017; 70: 1013-1028
        • Capodanno D
        • Petronio AS
        • Prendergast B
        • Eltchaninoff H
        • Vahanian A
        • Modine T
        • Lancellotti P
        • Sondergaard L
        • Ludman PF
        • Tamburino C
        • Piazza N
        • Hancock J
        • Mehilli J
        • Byrne RA
        • Baumbach A
        • Kappetein AP
        • Windecker S
        • Bax J
        • Haude M.
        Standardized definitions of structural deterioration and valve failure in assessing long-term durability of transcatheter and surgical aortic bioprosthetic valves: a consensus statement from the European Association of Percutaneous Cardiovascular Interventions (EAPCI) endorsed by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
        Eur J Cardiothorac Surg. 2017; 52: 408-417
        • Vohra HA
        • Whistance RN
        • Roubelakis A
        • Burton A
        • Barlow CW
        • Tsang GMK
        • Livesey SA
        • Ohri SK.
        Outcome after redo-mitral valve replacement in adult patients: a 10-year single-centre experience.
        Interact Cardiovasc Thorac Surg. 2012; 14: 575-579
        • Jones JM
        • O'Kane H
        • Gladstone DJ
        • Sarsam MAI
        • Campalani G
        • MacGowan SW
        • Cleland J
        • Cran GW
        Repeat heart valve surgery: risk factors for operative mortality.
        J Thorac Cardiovasc Surg. 2001; 122: 913-918
        • Balsam LB
        • Grossi EA
        • Greenhouse DG
        • Ursomanno P
        • Deanda A
        • Ribakove GH
        • Culliford AT
        • Galloway AC.
        Reoperative valve surgery in the elderly: predictors of risk and long-term survival.
        Ann Thorac Surg. 2010; 90: 1195-1201
        • Murzi M
        • Berti S
        • Gasbarri T
        • Trianni G
        • Maffei S
        • Solinas M
        • Dvir D
        • Cerillo AG.
        Transapical transcatheter mitral valve-in-valve implantation versus minimally invasive surgery for failed mitral bioprostheses.
        Interact Cardiovasc Thorac Surg. 2017; 25: 57-61
        • Kamioka N
        • Babaliaros V
        • Morse MA
        • Frisoli T
        • Lerakis S
        • Iturbe JM
        • Binongo J
        • Corrigan F
        • Yousef A
        • Gleason P
        • Wells JA
        • Caughron H
        • Dong A
        • Rodriguez E
        • Leshnower B
        • O'Neill W
        • Paone G
        • Eng M
        • Guyton R
        • Block PC
        • Greenbaum A
        Comparison of clinical and echocardiographic outcomes after surgical redo mitral valve replacement and transcatheter mitral valve-in-valve therapy.
        JACC Cardiovasc Interv. 2018; 11: 1131-1138
        • Simonetto F
        • Purita PAM
        • Malerba M
        • Barbierato M
        • Pascotto A
        • Mangino D
        • Zanchettin C
        • Tarantini G
        • Gerosa G
        • D'Onofrio A
        • Cernetti C
        • Favero L
        • Daniotti A
        • Minniti G
        • Caprioglio F
        • Erente G
        • Hinna Danesi T
        • Frigo AC
        • Ronco F
        Surgical redo versus transseptal or transapical transcatheter mitral valve-in-valve implantation for failed mitral valve bioprosthesis.
        Catheter Cardiovasc Interv. 2021; 97: 714-722
        • Houchens RL
        • Ross D
        • Elixhauser A
        Using the HCUP National Inpatient Sample to Estimate Trends.
        HCUP Methods Series U.S. Agency for Healthcare Research and Quality. 2015; (Available at:) (Accessed on January 4, 2016)
        • Cheung A
        • Webb JG
        • Wong DR
        • Ye J
        • Masson JB
        • Carere RG
        • Lichtenstein SV.
        Transapical transcatheter mitral valve-in-valve implantation in a human.
        Ann Thorac Surg. 2009; 87: e18-e20
        • Guerrero M
        • Vemulapalli S
        • Xiang Q
        • Wang DD
        • Eleid M
        • Cabalka AK
        • Sandhu G
        • Salinger M
        • Russell H
        • Greenbaum A
        • Kodali S
        • George I
        • Dvir D
        • Whisenant B
        • Russo MJ
        • Pershad A
        • Fang K
        • Coylewright M
        • Shah P
        • Babaliaros V
        • Khan JM
        • Tommaso C
        • Saucedo J
        • Kar S
        • Makkar R
        • Mack M
        • Holmes D
        • Leon M
        • Bapat V
        • Thourani VH
        • Rihal C
        • O'Neill W
        • Feldman T
        Thirty-day outcomes of transcatheter mitral valve replacement for degenerated mitral bioprostheses (valve-in-valve), failed surgical rings (valve-in-ring), and native valve with severe mitral annular calcification (valve-in-mitral annular calcification) in the United States: data from the Society of Thoracic Surgeons/American College of Cardiology/Transcatheter Valve Therapy Registry.
        Circ Cardiovasc Interv. 2020; 13e008425
        • Kalra A
        • Raza S
        • Hussain M
        • Shorbaji K
        • Delozier S
        • Deo SV.
        • Khera S
        • Kleiman NS
        • Reardon MJ
        • Kolte D
        • Gupta T
        • Mustafa R
        • Bhatt DL
        • Sabik JF.
        Aortic valve replacement in bioprosthetic failure: insights from the Society of Thoracic Surgeons national database.
        Ann Thorac Surg. 2020; 110: 1637-1642
        • Nishimura RA
        • Otto CM
        • Bonow RO
        • Carabello BA
        • Erwin JP
        • Fleisher LA
        • Jneid H
        • Mack MJ
        • McLeod CJ
        • O'Gara PT
        • Rigolin VH
        • Sundt TM
        • Thompson A.
        2017 AHA/ACC Focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.
        Circulation. 2017; 135: e1159-e1195
        • Silaschi M
        • Wendler O
        • Seiffert M
        • Castro L
        • Lubos E
        • Schirmer J
        • Blankenberg S
        • Reichenspurner H
        • Schäfer U
        • Treede H
        • MacCarthy P
        • Conradi L.
        Transcatheter valve-in-valve implantation versus redo surgical aortic valve replacement in patients with failed aortic bioprostheses.
        Interact Cardiovasc Thorac Surg. 2017; 24: 63-70
        • Nalluri N
        • Atti V
        • Munir AB
        • Karam B
        • Patel NJ
        • Kumar V
        • Vemula P
        • Edla S
        • Asti D
        • Paturu A
        • Gayam S
        • Spagnola J
        • Barsoum E
        • Maniatis GA
        • Tamburrino F
        • Kandov R
        • Lafferty J
        • Kliger C.
        Valve in valve transcatheter aortic valve implantation (ViV-TAVI) versus redo-Surgical aortic valve replacement (redo-SAVR): a systematic review and meta-analysis.
        J Interv Cardiol. 2018; 31: 661-671
        • Tam DY
        • Vo TX
        • Wijeysundera HC
        • Dvir D
        • Friedrich JO
        • Fremes SE.
        Transcatheter valve-in-valve versus redo surgical aortic valve replacement for the treatment of degenerated bioprosthetic aortic valve: a systematic review and meta-analysis.
        Catheter Cardiovasc Interv. 2018; 92: 1404-1411
        • Garatti A
        • Daprati A
        • Cottini M
        • Russo CF
        • M Dalla Tomba
        • Troise G
        • Salsano A
        • Santini F
        • Scrofani R
        • Nicolò F
        • Mikus E
        • Albertini A
        • Di Marco L
        • Pacini D
        • Picichè M
        • Salvador L
        • Actis Dato GM
        • Centofanti P
        • Paparella D
        • Kounakis G
        • Parolari A
        • Menicanti L
        • Italian Group of Research for Outcome in Cardiac Surgery (GIROC)
        Cardiac surgery in patients with liver cirrhosis (CASTER) study: early and long-term outcomes.
        Ann Thorac Surg. 2021; 111: 1242-1251
        • Nashef SAM
        • Roques F
        • Sharples LD
        • Nilsson J
        • Smith C
        • Goldstone AR
        • Lockowandt U.
        EuroSCORE II.
        Eur J Cardiothorac Surg. 2012; 41 (discussion 744): 734-744
        • Shahian DM
        • Jacobs JP
        • Badhwar V
        • Kurlansky PA
        • Furnary AP
        • Cleveland JC
        • Lobdell KW
        • Vassileva C
        • Wyler Von Ballmoos MC
        • Thourani VH
        • Rankin JS
        • Edgerton JR
        • D'agostino RS
        • Desai ND
        • Feng L
        • He X
        • O'Brien SM
        The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: part 1-background, design considerations, and model development. 2018.
        Ann Thorac Surg. 2018 May; 105: 1411-1418
      1. O'Brien SM, Feng L, He X, Xian Y, Jacobs JP, Badhwar V, Kurlansky PA, Furnary AP, Cleveland JC, Lobdell KW, Vassileva C, Wyler von Ballmoos MC, Thourani VH, Rankin JS, Edgerton JR, D'Agostino RS, Desai ND, Edwards FH, Shahian DM. The Society of Thoracic Surgeons 2018 Adult Cardiac Surgery Risk Models: part 2-statistical methods and results. Ann Thorac Surg.105:1419–1428.

        • Dimarakis I
        • Grant S
        • Corless R
        • Velissaris T
        • Prince M
        • Bridgewater B
        • Asimakopoulos G.
        Impact of hepatic cirrhosis on outcome in adult cardiac surgery.
        Thorac Cardiovasc Surg. 2015; 63: 58-66
        • Lak HM
        • Chawla S
        • Gajulapalli RD
        • Verma BR
        • Vural AF
        • Gad M
        • Nair R
        • Shekhar S
        • Quintini C
        • Menon KVN
        • Yun J
        • Burns D
        • Reed GW
        • Puri R
        • Harb S
        • Krishnaswamy A
        • Fares M
        • Kapadia SR.
        Outcomes after transfemoral transcatheter aortic valve implantation with a SAPIEN 3 valve in patients with cirrhosis of the liver (a tertiary care center experience).
        Am J Cardiol. 2021; 160: 75-82
        • Lee DU
        • Han J
        • Fan GH
        • Hastie DJ
        • Kwon J
        • Lee KJ
        • Addonizio EA
        • Karagozian R.
        The clinical impact of chronic liver disease in patients undergoing transcatheter and surgical aortic valve replacement: systematic analysis of the 2011–2017 US hospital database.
        Catheter Cardiovasc Interv. 2021; 98: E1044-E1057
        • Ahmed T
        • Misumida N
        • Grigorian A
        • Tarantini G
        • Messerli AW.
        Transcatheter interventions for valvular heart diseases in liver cirrhosis patients.
        Trends Cardiovasc Med. 2021;
        • Ghanta RK
        • LaPar DJ
        • Zhang Q
        • Devarkonda V
        • Isbell JM
        • Yarboro LT
        • Kern JA
        • Kron IL
        • Speir AM
        • Fonner CE
        • Ailawadi G.
        Obesity increases risk-adjusted morbidity, mortality, and cost following cardiac surgery.
        J Am Heart Assoc. 2017; 6
        • Unosawa S
        • Taoka M
        • Osaka S
        • Yuji D
        • Kitazumi Y
        • Suzuki K
        • Kamata K
        • Sezai A
        • Tanaka M.
        Is malnutrition associated with postoperative complications after cardiac surgery?.
        J Card Surg. 2019; 34: 908-912
        • Al-Sarraf N
        • Raza A
        • Rowley S
        • Hughes A
        • Tolan M
        • Young V
        • McGovern E.
        Short-term and long-term outcome in low body mass index patients undergoing cardiac surgery.
        Gen Thorac Cardiovasc Surg. 2009; 57: 87-93
        • Goode D
        • Dhaliwal R
        • Mohammadi H.
        Transcatheter mitral valve replacement: state of the art.
        Cardiovasc Eng Technol. 2020; 11: 229-253
        • Whisenant B
        • Kapadia SR
        • Eleid MF
        • Kodali SK
        • McCabe JM
        • Krishnaswamy A
        • Morse M
        • Smalling RW
        • Reisman M
        • Mack M
        • O'Neill WW
        • Bapat VN
        • Leon MB
        • Rihal CS
        • Makkar RR
        • Guerrero M
        One-year outcomes of mitral valve-in-valve using the SAPIEN 3 transcatheter heart valve.
        JAMA Cardiol. 2020; 5: 1245-1252